University of Notre Dame's Idea Center formed two spinouts in 2019 to market topical ulcer treatments and bespoke gifts for university benefactors.

3M, CareFirst BlueCross BlueShield, Lafayette General Health, OSF Healthcare and ProMedica all invested as the healthcare technology provider closed an $11.1m round.

Revolution Medicines, based on research from University of Illinois at Urbana-Champaign, Stanford University and UC Berkeley, has filed for a $100m initial public offering.

Sanofi is in line for an exit as Revolution Medicines files for a $100m initial public offering on the Nasdaq Global Market.

University Hospital Tübingen's liver disease treatment spinout HepaRegenix has raised $21.6m in all following a series B round that featured Novo and Boehringer Ingelheim.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

University Hospital Tübingen's liver disease treatment spinout HepaRegenix has raised $21.6m in all following a series B round that will fund trials of its first candidate.

MassMutual Ventures has followed up on the $50m Southeast Asian fund it launched in late 2018 with a second vehicle dedicated to the region.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The Tasly and Genexine-backed drug developer floated above the mid-point of its range, in an initial public offering that could end up topping $119m.